Zevra Therapeutics (ZVRA) AI Stock Analysis

• Market Cap: $499.60M
• Dividend Yield: N/A
• Average Volume (3M): 1.45M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: 158.57%
• EPS Growth: 96.76%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 1.21
• Shares Outstanding: 56,135,090
• 10 Day Avg. Volume: 1,601,587
• 30 Day Avg. Volume: 1,450,729
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.69
• Enterprise Value/Revenue: 5.52
• Enterprise Value/Gross Profit: 7.67
• Enterprise Value/Ebitda: -2.97
• 1Y Price Target: $21.93
• Price Target Upside: 132.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 47 Neutral
• Price Target: $9.50 ▲(0.74% Upside)

Zevra Therapeutics' stock score is primarily impacted by its financial performance and technical analysis. While the company shows strong revenue growth, its negative operating margins and cash flow issues pose significant risks. The bearish technical indicators further weigh on the stock's outlook. Valuation concerns, highlighted by a negative P/E ratio, also contribute to the lower score.

Positive Factors

Early Commercial Success

Miplyffa's early commercial success and the monetization of the Priority Review Voucher significantly drove ZVRA shares up.

Financial Stability

ZVRA remains well-capitalized, suggesting financial stability and less immediate need for capital raises.

Potential EU Market Opportunity

The submission of a Marketing Authorization Application to the European Medicines Agency for arimoclomol is a positive step towards unlocking a meaningful value creation opportunity for the company.

Negative Factors

Olpruva Challenges

Despite strong results for Miplyffa, ZVRA shares are down due to issues with Olpruva.

Patient Enrollment Slowdown

Olpruva continues to benefit from synergistic commercial infrastructure with Miplyffa, but new patient starts are still slow.

Slow Adoption

Adoption of Olpruva has been slower due to the mature UCD market and strong patient satisfaction with existing treatments.

Zevra Therapeutics Business Overview & Revenue Model

Company Description

Zevra Therapeutics (ZVRA) is a biopharmaceutical company focused on developing innovative therapies for patients with rare and complex diseases. The company specializes in advancing novel treatments that target unmet medical needs, leveraging its proprietary drug development platforms. Zevra's core products include therapies aimed at neurological and metabolic disorders, with a strong emphasis on delivering effective solutions for conditions that currently lack adequate treatment options.

How the Company Makes Money

Zevra Therapeutics generates revenue primarily through the commercialization of its pharmaceutical products, which involves selling approved therapies to healthcare providers and patients. The company may also engage in licensing agreements and partnerships with larger pharmaceutical companies for the co-development and distribution of its drugs, providing additional revenue streams through upfront payments, milestone payments, and royalties on future sales. Additionally, funding from government grants and research institutions to support clinical trials can contribute to its earnings. As Zevra advances its drug candidates through clinical trials and regulatory approvals, successful product launches and market penetration are critical for driving its financial performance.

Zevra Therapeutics Financial Statement Overview

Summary

Zevra Therapeutics faces considerable financial challenges, with consistent losses and reliance on external financing. While the company demonstrates strong gross profit margins, its high leverage and negative profitability metrics pose significant risks. The cash flow situation is concerning, with negative free cash flow and reliance on financing activities. Overall, the company needs to improve its profitability and cash flow management to ensure long-term sustainability.

Income Statement

Zevra Therapeutics shows a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) gross profit margin is strong at 78.87%, indicating efficient cost management relative to revenue. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -226.63% and a negative EBIT margin of -177.09%. Revenue growth is inconsistent, with a notable increase in the latest period but a decline in previous years. The negative EBITDA margin of -165.97% further highlights operational challenges.

Balance Sheet

The balance sheet of Zevra Therapeutics reflects a high debt-to-equity ratio of 1.51, suggesting significant leverage and potential financial risk. The equity ratio is low at 23.76%, indicating limited equity financing. Return on equity is negative at -224.27%, reflecting ongoing losses. Despite these challenges, the company maintains a reasonable level of cash and short-term investments, which provides some liquidity cushion.

Cash Flow

Cash flow analysis reveals significant challenges for Zevra Therapeutics. The operating cash flow to net income ratio is 0.67, indicating that cash flow from operations is insufficient to cover net losses. Free cash flow is negative, and the free cash flow to net income ratio is 0.67, highlighting cash constraints. The company relies heavily on financing activities to support operations, which could pose risks if external funding becomes less accessible.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	62.02M	23.61M	27.46M	10.16M	28.65M	13.29M
Gross Profit	44.63M	16.20M	24.52M	9.94M	26.59M	11.98M
EBITDA	-115.16M	-76.40M	-43.54M	-25.53M	-7.89M	-5.43M
Net Income	2.64M	-105.51M	-46.05M	-26.77M	-8.55M	-12.76M
Balance Sheet
Total Assets	256.28M	178.13M	172.33M	115.53M	132.94M	11.21M
Cash, Cash Equivalents and Short-Term Investments	47.71M	69.50M	67.74M	82.85M	112.35M	4.21M
Total Debt	62.28M	60.30M	43.77M	14.12M	1.61M	70.35M
Total Liabilities	139.05M	138.46M	110.46M	40.22M	5.82M	77.62M
Stockholders Equity	117.23M	39.67M	61.86M	75.12M	127.12M	-66.41M
Cash Flow
Free Cash Flow	-46.53M	-69.67M	-33.83M	-18.81M	10.34M	-1.97M
Operating Cash Flow	-46.21M	-69.67M	-33.53M	-18.72M	10.44M	-1.94M
Investing Cash Flow	-14.35M	-22.16M	-17.39M	-36.72M	-15.52M	-33.00K
Financing Cash Flow	68.55M	82.11M	28.46M	8.35M	113.11M	2.74M

Zevra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.43
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVRA, the sentiment is Negative. The current price of 9.43 is below the 20-day moving average (MA) of 11.12, below the 50-day MA of 10.54, and above the 200-day MA of 8.73, indicating a neutral trend. The MACD of -0.20 indicates Positive momentum. The RSI at 36.28 is Neutral, neither overbought nor oversold. The STOCH value of 15.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZVRA.

Zevra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$18.32B	5.55	-4.00%	3.32%	9.92%	-18.97%
MAZE	59 Neutral	$585.41M	―		―	―	―
RLAY	55 Neutral	$584.47M	―	-46.24%	―	-76.27%	22.77%
UPB	54 Neutral	$1.00B	―		―	―	―
ZVRA	47 Neutral	$499.60M	―	3.53%	―	158.57%	96.76%
OMER	40 Underperform	$276.56M	―	87.26%	―	―	-33.92%

Zevra Therapeutics Corporate Events

Zevra Therapeutics Elects New Directors at Annual Meeting

On May 29, 2025, Zevra Therapeutics held its Annual Meeting of Stockholders where Wendy Dixon, Ph.D., and Tamara A. Favorito were elected as directors. The meeting also saw the ratification of Ernst & Young LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. The election process was marked by the disqualification of nominees proposed by stockholder Daniel J. Mangless due to non-compliance with legal requirements and company bylaws, ensuring the election of the company’s preferred candidates.

The most recent analyst rating on (ZVRA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Zevra Therapeutics stock, see the ZVRA Stock Forecast page.